Oncology

Rondo Therapeutics

Developing new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti-tumor response.

Red Tree Participation
Co-led Series A

Red Tree Board Member

Jon Edwards, Ph.D.

Total Addressable Market

$10 billion+

Red Tree Board Member(s)

Red Tree Board Member

Jon Edwards, Ph.D.

Red Tree Participation
Co-led Series A

Rondo Therapeutics

Oncology
Total Addressable Market

$10 billion+

Red Tree Board Member(s)

Red Tree Board Member

Jon Edwards, Ph.D.

Red Tree Participation
Co-led Series A